Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.59 |
| ▸ | BRAF | P15056 | 10/20 | 0.59 |
| ▸ | SRC | P12931 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.51 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.51 |
| ▸ | RET | P07949 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.51 |
| ▸ | TEK | Q02763 | 3/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545589 | 0.86 | BRAF (0.60) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL545309 | 0.79 | RAF1 (0.63) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL5438830 | 0.79 | KDR (0.62) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL5423039 | 0.77 | BRAF (0.60) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL5423862 | 0.76 | KDR (0.54) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL545427 | 0.75 | RAF1 (1.00) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL3541813 | 0.74 | RAF1 (0.79) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL3540263 | 0.74 | RAF1 (0.58) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL3540267 | 0.74 | RAF1 (0.58) | RAF1BRAFSRCKDRMAPK14 | |
| SCHEMBL10199839 | 0.73 | RAF1 (0.48) | RAF1BRAFSRCKDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | RAF1 198/4885BRAF 215/4885SRC 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.